Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q1 EPS of ($0.39), $0.03 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $13.79 million versus the consensus estimate of $11.3 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.